Editorial: Translating NK cell scientific research to clinical product manufacturing.
作者信息
Ullrich Evelyn, Huppert Volker, Tonn Torsten, Leung Wing
机构信息
Experimental Immunology & Cell Therapy, Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany.
Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany.
出版信息
Front Immunol. 2023 Aug 23;14:1229417. doi: 10.3389/fimmu.2023.1229417. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Translating NK cell scientific research to clinical product manufacturing.社论：将自然杀伤细胞科研成果转化为临床产品制造
Front Immunol. 2023 Aug 23;14:1229417. doi: 10.3389/fimmu.2023.1229417. eCollection 2023.
2
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.学术界的先进疗法医学产品（ATMP）开发与临床前药品生产质量管理规范（pre-GMP）环境：早期细胞和基因疗法开发与制造的安全保障
Immunooncol Technol. 2022 Oct 6;16:100099. doi: 10.1016/j.iotech.2022.100099. eCollection 2022 Dec.
3
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.用于原代人自然杀伤细胞临床规模制造及α逆转录病毒嵌合抗原受体工程的自动化分离、扩增和质量控制方案的开发。
Hum Gene Ther Methods. 2019 Jun;30(3):102-120. doi: 10.1089/hgtb.2019.039. Epub 2019 May 16.
4
Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.符合良好生产规范的细胞分选和大规模扩增单个 KIR 阳性同种反应性人自然杀伤细胞，以用于多次输注给白血病患者。
Cytotherapy. 2010 Oct;12(6):750-63. doi: 10.3109/14653241003786155.
5
GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration.用于个性化治疗年龄相关性黄斑变性的非病毒工程化先进治疗药物产品的GMP级生产与质量控制
Biomedicines. 2022 Nov 1;10(11):2777. doi: 10.3390/biomedicines10112777.
6
Natural Killer Cells for Therapy of Leukemia.用于白血病治疗的自然杀伤细胞
Transfus Med Hemother. 2016 Mar;43(2):89-95. doi: 10.1159/000445325. Epub 2016 Mar 22.
7
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.人自然杀伤细胞制备的优化：全自动分离，使用 IL-21 和自体饲养细胞进行体外扩增的改进，以及生成表达抗 CD123-CAR 的效应细胞。
Hum Gene Ther. 2017 Oct;28(10):897-913. doi: 10.1089/hum.2017.157. Epub 2017 Aug 15.
8
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.临床开发中的自然杀伤细胞作为非工程化、工程化和联合疗法。
J Hematol Oncol. 2022 Nov 8;15(1):164. doi: 10.1186/s13045-022-01382-5.
9
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.在良好生产规范条件下产生的细胞因子诱导的杀伤细胞：从活力、细胞生长和特性方面确定最有利和最安全的扩增方法。
J Transl Med. 2018 Aug 29;16(1):237. doi: 10.1186/s12967-018-1613-5.
10
Upgrading Monocytes Therapy for Critical Limb Ischemia Patient Treatment: Pre-Clinical and GMP-Validation Aspects.升级单核细胞疗法治疗严重肢体缺血患者：临床前和 GMP 验证方面。
Int J Mol Sci. 2022 Oct 21;23(20):12669. doi: 10.3390/ijms232012669.
本文引用的文献
1
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.在复发性胶质母细胞瘤患者中，经 HER2 靶向嵌合抗原受体工程化的自然杀伤细胞颅内注射。
Neuro Oncol. 2023 Nov 2;25(11):2058-2071. doi: 10.1093/neuonc/noad087.
2
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.临床开发中的自然杀伤细胞作为非工程化、工程化和联合疗法。
J Hematol Oncol. 2022 Nov 8;15(1):164. doi: 10.1186/s13045-022-01382-5.
3
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
4
The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.越多越好：急性髓系白血病自然杀伤细胞免疫疗法的“正确做法”
Front Immunol. 2017 Oct 19;8:1330. doi: 10.3389/fimmu.2017.01330. eCollection 2017.
5
Successful Transfer of Umbilical Cord Blood CD34 Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients.脐带血 CD34+ 造血干/祖细胞来源的 NK 细胞在老年急性髓系白血病患者中成功转移。
Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.
6
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.NKAML 研究：一项初步研究，旨在确定亲缘单倍体自然杀伤细胞移植治疗儿童急性髓系白血病的安全性和可行性。
J Clin Oncol. 2010 Feb 20;28(6):955-9. doi: 10.1200/JCO.2009.24.4590. Epub 2010 Jan 19.
7
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.自然杀伤细胞同种异体反应性与异基因造血干细胞移植
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90. doi: 10.1016/j.bcmd.2007.06.029. Epub 2007 Oct 26.
8
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.人类单倍体相合自然杀伤细胞在癌症患者中的成功过继转移及体内扩增。
Blood. 2005 Apr 15;105(8):3051-7. doi: 10.1182/blood-2004-07-2974. Epub 2005 Jan 4.
9
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.供体自然杀伤细胞同种异体反应性在不匹配造血移植中的有效性。
Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
10
Surveillance of primitive cells by natural killer cells.自然杀伤细胞对原始细胞的监测。
Curr Top Microbiol Immunol. 1981;92:107-23. doi: 10.1007/978-3-642-68069-4_7.
Zotero 插件